# Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM

> **NCT07014735** · NA · RECRUITING · sponsor: **Richmond Pharmacology Limited** · enrollment: 24 (estimated)

## Conditions studied

- Diabetes Type 2
- Hyperglycaemia (Diabetic)
- QT Interval, Variation in
- Torsades de Pointes

## Interventions

- **DRUG:** glucose
- **DRUG:** moxifloxacin

## Key facts

- **NCT ID:** NCT07014735
- **Lead sponsor:** Richmond Pharmacology Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-13
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014735, "Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07014735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*